Cargando…

Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma

SIMPLE SUMMARY: Cereblon (CRBN) is a direct binding target of immunomodulatory drugs (IMiDs) that are commonly used to treat multiple myeloma (MM). Many patients with MM have comorbidities, including diabetes and/or dyslipidemia, and are treated with peroxisome proliferator-activated receptor (PPAR)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jian, Chu, Emily, Paul, Barry, Kang, Yubin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657746/ https://www.ncbi.nlm.nih.gov/pubmed/36358696 http://dx.doi.org/10.3390/cancers14215272

Ejemplares similares

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

PIM Kinases in Multiple Myeloma
por: Wu, Jian, et al.
Publicado: (2021)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors
por: Paul, Barry, et al.
Publicado: (2020)

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
por: Chu, Emily, et al.
Publicado: (2023)

Anaplastic Multiple Myeloma: Case Series and Literature Review
por: Wu, Jian, et al.
Publicado: (2022)

Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
por: Patel, Urmeel H., et al.
Publicado: (2015)

Adherence to immunomodulatory drugs in patients with multiple myeloma
por: Cransac, Amélie, et al.
Publicado: (2019)

Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma
por: Rizzieri, Dustin, et al.
Publicado: (2019)

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
por: Abdallah, Al‐Ola, et al.
Publicado: (2021)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
por: Vella, Veronica, et al.
Publicado: (2017)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
por: Chen, Lucia Y., et al.
Publicado: (2022)

RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect
por: Wu, Jian, et al.
Publicado: (2023)

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma
por: Vlummens, Philip, et al.
Publicado: (2019)

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
por: Swan, Dawn, et al.
Publicado: (2020)

Innovative Agents in Multiple Myeloma
por: Faiman, Beth, et al.
Publicado: (2014)

Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation or Treated with Immunomodulatory Agents.
por: Khalafallah, Alhossain, et al.
Publicado: (2010)

Development of oral immunomodulatory agents in the management of multiple sclerosis
por: Nicholas, Richard, et al.
Publicado: (2011)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

PPAR Agonists and Cardiovascular Disease in Diabetes
por: Calkin, Anna C., et al.
Publicado: (2008)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
por: Hideshima, T, et al.
Publicado: (2015)

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
por: De Beck, Lien, et al.
Publicado: (2018)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
por: Bisht, Kamlesh, et al.
Publicado: (2023)

Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high‐risk multiple myeloma in Asian patients
por: Byun, Ja Min, et al.
Publicado: (2018)

Fact or fiction - identifying the elusive multiple myeloma stem cell
por: Kellner, Joshua, et al.
Publicado: (2013)

Bone-targeted agents in multiple myeloma
por: Nishida, Hiroko
Publicado: (2018)

Emerging agents and regimens for multiple myeloma
por: Yang, Yang, et al.
Publicado: (2020)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma
por: Chu, Tan-Huy, et al.
Publicado: (2022)

Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals
por: Niu, Ho-Shan, et al.
Publicado: (2015)

Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?
por: Scatena, Roberto, et al.
Publicado: (2008)

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
por: Cornell, Robert Frank, et al.
Publicado: (2019)

The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
por: Szabo, Agoston Gyula, et al.
Publicado: (2019)

Cannabinoids: A New Group of Agonists of PPARs
por: Sun, Yan, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_63i06gn43eu3gm91m3pigbf77q